Cervical Cancer - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Cervical Cancer - Pipeline Review, H1 2018’, provides an overview of the Cervical Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cervical Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cervical Cancer

- The report reviews pipeline therapeutics for Cervical Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Cervical Cancer therapeutics and enlists all their major and minor projects

- The report assesses Cervical Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Cervical Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cervical Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abion Inc

Abivax SA

Admedus Ltd

Advaxis Inc

Advenchen Laboratories LLC

Agenus Inc

Amgen Inc

AntiCancer Inc

Antigen Express Inc

ArQule Inc

Asana BioSciences LLC ...

Abion Inc

Abivax SA

Admedus Ltd

Advaxis Inc

Advenchen Laboratories LLC

Agenus Inc

Amgen Inc

AntiCancer Inc

Antigen Express Inc

ArQule Inc

Asana BioSciences LLC

Astex Pharmaceuticals Inc

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

Bioleaders Corp

Biomics Biotechnologies Co Ltd

Blirt SA

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cadila Healthcare Ltd

Cancer Research Technology Ltd

Celleron Therapeutics Ltd

Cellestia Biotech AG

Clovis Oncology Inc

Coherus BioSciences Inc

Corvus Pharmaceuticals Inc

Cotinga Pharmaceuticals Inc

Cytori Therapeutics Inc

CZ BioMed Corp

DelMar Pharmaceuticals Inc

Dr. Reddy's Laboratories Ltd

Eisai Co Ltd

Etubics Corp

Eureka Therapeutics Inc

EyeGene Inc

F. Hoffmann-La Roche Ltd

Formation Biologics Inc

Formune SL

GamaMabs Pharma SA

Gene Techno Science Co Ltd

Genentech Inc

Genetic Immunity Inc

Genexine Inc

Genmab A/S

GlaxoSmithKline Plc

Glycostem Therapeutics BV

Glycotope GmbH

Gradalis Inc

Immunomedics Inc

Immunovaccine Inc

Innate Pharma SA

Iovance Biotherapeutics Inc

ISA Pharmaceuticals BV

JHL Biotech Inc

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Kite Pharma Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Molecular Partners AG

Mycenax Biotech Inc

NeoImmuneTech Inc

Novartis AG

Ology Bioservices Inc

Oncobiologics Inc

Ono Pharmaceutical Co Ltd

Oxford Vacmedix UK Ltd

Pfizer Inc

Pharma Mar SA

Protheragen Inc

Puma Biotechnology Inc

Regeneron Pharmaceuticals Inc

Rexahn Pharmaceuticals Inc

Richter Gedeon Nyrt

Samyang Holdings Corp

Sanofi

Seattle Genetics Inc

Selecta Biosciences Inc

Shantha Biotechnics Pvt Ltd

Sierra Oncology Inc

Sirnaomics Inc

Sun Pharma Advanced Research Company Ltd

Tessa Therapeutics Pte Ltd

Theralase Technologies Inc

Theravectys SA

THEVAX Genetics Vaccine USA Inc

Transgene SA

Vectorite Biomedical Inc

Virometix AG

VLPbio

Zeria Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Cervical Cancer – Overview 9

Cervical Cancer – Therapeutics Development 10

Cervical Cancer – Therapeutics Assessment 30

Cervical Cancer ...

Table of Contents

Table of Contents 2

Introduction 8

Cervical Cancer – Overview 9

Cervical Cancer – Therapeutics Development 10

Cervical Cancer – Therapeutics Assessment 30

Cervical Cancer – Companies Involved in Therapeutics Development 44

Cervical Cancer – Drug Profiles 86

Cervical Cancer – Dormant Projects 733

Cervical Cancer – Discontinued Products 739

Cervical Cancer – Product Development Milestones 740

Appendix 750

List of Tables

List of Tables

Number of Products under Development for Cervical Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Tables

Number of Products under Development for Cervical Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Cervical Cancer – Pipeline by Abion Inc, H1 2018

Cervical Cancer – Pipeline by Abivax SA, H1 2018

Cervical Cancer – Pipeline by Admedus Ltd, H1 2018

Cervical Cancer – Pipeline by Advaxis Inc, H1 2018

Cervical Cancer – Pipeline by Advenchen Laboratories LLC, H1 2018

Cervical Cancer – Pipeline by Agenus Inc, H1 2018

Cervical Cancer – Pipeline by Amgen Inc, H1 2018

Cervical Cancer – Pipeline by AntiCancer Inc, H1 2018

Cervical Cancer – Pipeline by Antigen Express Inc, H1 2018

Cervical Cancer – Pipeline by ArQule Inc, H1 2018

Cervical Cancer – Pipeline by Asana BioSciences LLC, H1 2018

Cervical Cancer – Pipeline by Astex Pharmaceuticals Inc, H1 2018

Cervical Cancer – Pipeline by AstraZeneca Plc, H1 2018

Cervical Cancer – Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Cervical Cancer – Pipeline by Bayer AG, H1 2018

Cervical Cancer – Pipeline by BeiGene Ltd, H1 2018

Cervical Cancer – Pipeline by Bioleaders Corp, H1 2018

Cervical Cancer – Pipeline by Biomics Biotechnologies Co Ltd, H1 2018

Cervical Cancer – Pipeline by Blirt SA, H1 2018

Cervical Cancer – Pipeline by Boehringer Ingelheim GmbH, H1 2018

Cervical Cancer – Pipeline by Bristol-Myers Squibb Co, H1 2018

Cervical Cancer – Pipeline by Cadila Healthcare Ltd, H1 2018

Cervical Cancer – Pipeline by Cancer Research Technology Ltd, H1 2018

Cervical Cancer – Pipeline by Celleron Therapeutics Ltd, H1 2018

Cervical Cancer – Pipeline by Cellestia Biotech AG, H1 2018

Cervical Cancer – Pipeline by Clovis Oncology Inc, H1 2018

Cervical Cancer – Pipeline by Coherus BioSciences Inc, H1 2018

Cervical Cancer – Pipeline by Corvus Pharmaceuticals Inc, H1 2018

Cervical Cancer – Pipeline by Cotinga Pharmaceuticals Inc, H1 2018

Cervical Cancer – Pipeline by Cytori Therapeutics Inc, H1 2018

Cervical Cancer – Pipeline by CZ BioMed Corp, H1 2018

Cervical Cancer – Pipeline by DelMar Pharmaceuticals Inc, H1 2018

Cervical Cancer – Pipeline by Dr. Reddy's Laboratories Ltd, H1 2018

Cervical Cancer – Pipeline by Eisai Co Ltd, H1 2018

Cervical Cancer – Pipeline by Etubics Corp, H1 2018

Cervical Cancer – Pipeline by Eureka Therapeutics Inc, H1 2018

Cervical Cancer – Pipeline by EyeGene Inc, H1 2018

Cervical Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Cervical Cancer – Pipeline by Formation Biologics Inc, H1 2018

Cervical Cancer – Pipeline by Formune SL, H1 2018

List of Figures

List of Figures

Number of Products under Development for Cervical Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Figures

Number of Products under Development for Cervical Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports